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Abstract  
Introduction: Appreciation of the barriers and drivers affecting enrolment in randomised clinical 
trials (RCTs) is important for future trial design, communication and information provision. 
 
Method: As part of an intervention to facilitate UK multidisciplinary team communication about 
RCTs, women with breast cancer who discussed trials with doctors and/or research nurses 
completed questionnaires examining: - clarity of trial information and reasons for either 
accepting or declining trial entry. 
Results: 152 women with breast cancer completed the questionnaires; 113/152 (74%) 
consented to RCT enrolment. Patients’ satisfaction with communication about the trial 
information was very good, irrespective of participation decisions. Acceptors’ and decliners’ 
responses to 9/16 statements concerning decisions about trial participation differed significantly. 
‘Wanting to help with doctor’s research’ influenced 100% acceptors compared to 57% of 
decliners (p<.001). Decliners were more likely to be ‘worried about randomisation’ (20% v 39%; 
p<.035) and to ‘want doctor to choose treatment rather than be randomised’ (31% v 53%; 
p<.031). Primary reason for trial acceptance was altruism; “I feel that others with my illness will 
benefit from the results of the trial”, 58/108 (54%).  
Conclusion:  A majority of women accepted RCT entry citing altruistic motivations as the 
primary driver for participation.  Trial design and setting (metastatic or adjuvant) had little impact 
on participation. 
 
 
  
Keywords 
Breast cancer, randomised clinical trials, and patients’ reasons 
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Introduction 
Appreciation of the barriers and drivers affecting enrolment in randomised clinical trials (RCTs) 
is important.  A lack of awareness of the factors influencing participation can lead to overly 
optimistic predictions of likely enrolment numbers and slow recruitment.  Not all patients join 
RCTs; understanding some of the reasons for rejecting participation is useful to inform future 
information, communication needs and trial design.   
 
Patients’ attitudes towards trials are generally positive, but the concept of randomisation is a 
difficult one for many to comprehend, [1-3]. Randomisation emerged as a major barrier in one 
study with women more likely than men to be dissuaded from trial entry when randomisation 
was introduced [4]. Also cultural differences are found, for example a US study reported that 
African American women with breast cancer had significantly more negative attitudes towards 
RCTs than others, which furthermore were not altered by an interventional explanatory video 
[5]. However, a survey that examined racial/ethnic factors in trial involvement noted that the 
length of the patient information pamphlet (>20 pages) was significantly associated with a lower 
odds of “no desire to participate” rather than ethnicity [6].    
 
Age can be another barrier to trial recruitment. A review of studies examining barriers to 
participation in breast cancer trials for older women showed that potential toxicities and co-
morbidity related questions represented the main obstacles for clinicians, whereas 
randomisation was of more concern to patients [7].  
 
Throughout the course of treatment there are many opportunities for women with breast cancer 
to engage in clinical trials, for example in the perioperative period, in the adjuvant and/or 
metastatic setting.  Some may question the ethics of engaging patients in more than one trial, 
but many would consider entering more than one study and believe there should not be a limit 
on the number offered [8].   
 
Although trials may address pertinent scientific questions, not all trial designs are equally 
attractive to patients. One study of 204 patients, 112 of whom were women with breast cancer, 
showed a significantly higher acceptance rate for trials providing active treatment in every arm 
(81%) compared with trials with a no treatment arm (61%) [9]. Often trials have multiple 
treatment arms, and this complexity of randomisation to four or more different treatment groups 
can be quite overwhelming.  In the case of breast cancer, a growing number of trials are 
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perioperative, and require extra tumour samples or additional imaging that may delay surgery.  
Other trial designs might offer a novel treatment compared with standard therapy, or a longer 
duration of standard treatment, which some patients may assume must be better. While the 
scientific community regards trials with placebo control and a no treatment arm as the 
scientifically purest design for testing the efficacy of new therapies, they may be least favoured 
by patients who in the face of potentially life threatening disease want an overtly active 
treatment.   Interestingly, a survey of >115,000 cancer patients in the USA reported that those 
with poor prognosis tumours, (e.g. ovarian) and those with advanced disease (e.g. metastatic 
breast cancer) were most likely to request study information about trials compared with those 
contemplating adjuvant treatments [10].   
 
The results presented in this paper examine the barriers and drivers affecting recruitment to 
breast cancer trials in UK women. The data were gathered as part of a larger Cancer Research 
UK (CRUK) funded prospective study that examined multidisciplinary team (MDT) members’ 
communication about RCTs [11]. 
 
Materials and methods 
Patients, who had discussed a trial with a doctor and/or research nurse from any of the 24 
multidisciplinary teams participating in the CRUK study, were given 2 study-specific 
questionnaires to complete at home and return by post to the co-ordinating centre. Each team 
were asked to provide monthly information regarding the number of patients who were given the 
questionnaires, together with their age and sex. The study had multicentre ethical approval 
(South East Wales Local Research Ethics Committee Ref: 07/WSE03/17) and local NHS R&D 
permissions. This paper deals with only the responses from the women with breast cancer. 
 
The questionnaires probed:- 
a) Reasons for accepting or declining trial entry & main reason for choice  
This study-specific16-item questionnaire was modified from Penman et al [12] and used in 
previous research of Phase 3 trials [13]. The questionnaire comprises an initial question 
establishing whether or not the patient has agreed to trial entry. For each of the 16 statements, 
patients registered their agreement or disagreement on a scale of 0 to 4 (0 strongly agree; 
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1agree to some extent; 2 unsure; 3 disagree to some extent; and 4 strongly disagree). Finally, 
patients indicated from the options available the most important reason for their decision. 
b) Clarity of communication  
This 15-item questionnaire was used to rate the clarity of the trial information provided by the 
team member. First, patients indicated who had spoken with them about the trial (e.g. research 
nurse or clinician) and where possible the name of the trial. Thereafter, patients rated their 
agreement with statements using a scale of 0 to 4 (0 not at all clear; 1 a little bit clear; 2 
somewhat clear; 3 quite a bit clear; and 4 very clear). These statements included clarity about 
explanations of randomisation and side effects of treatments. It has been used in a previous 
communication study with simulated patients [14]. 
 
Statistical analyses 
Summary statistics were generated for the descriptive data: counts, percentages and averages. 
Chi-square tests with continuity corrections as appropriate were conducted on comparison data. 
Type of trial was categorised by entering the name of the trial from the patient questionnaires 
into the National Cancer Research Network and CRUK trial databases. We devised 3 trial 
categories; placebo control, standard vs new therapy/regimen, standard therapy +/- new agent. 
Trial type also allowed us to categorise the patients as receiving treatment for adjuvant or 
advanced disease. Previous trial experience was unknown. 
Results 
Sample 
Cancer teams recruited 152 women with breast cancer to the communication study over a 
period of 3 years. Participants were aged between 29 and 87 years of age (Table 1); the 
majority (65%) were in the age group 51-69 years.   
Most women indicated that the trial information was provided more often by the research nurse 
(111/146; 76%) than by the doctor (28/146; 19%), although a few reported both (7; 5%); 
reflecting UK practice. The majority of women (113/152; 74%) agreed to participate in a trial, 
31/152 (20%) declined and 8 (5%) were unsure if they were in a trial or not. Most of the trials 
offered were in the adjuvant setting (110/140; 79%), rather than for treatment of advanced or 
metastatic disease (30/140; 21%).  Table 2 shows acceptance rate by trial type with an example 
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of a trial for each category. There was no significant difference in acceptance rates by trial 
design (chi2 =8.066, df =1, p=0.89) but a smaller proportion of those offered standard +/- a new 
treatment agreed to trial participation (64%) compared to the other two trial designs (standard v 
new regimen/new treatment: 81%; placebo control: 73%). The majority of women offered a 
standard +/- new treatment trial was in the adjuvant setting (84%v16%). 
Examination of the individual statements for patients who accepted or declined trial entry, 
showed significantly different responses for 9/16 statements (Table 3). Patients who declined 
trial entry were: more likely to be concerned about randomisation, whether the benefit of the trial 
treatment would outweigh side effects; did not feel that they wanted to help with the doctor’s 
research, and fewer agreed that family and friends wanted them to join the trial. The primary 
reason for trial acceptance was altruism ““I feel that others with my illness will benefit from the 
results of trial”, (58/108; 54%) and “trust in the doctor” for those who declined a trial (7/31; 23%).  
Although altruism was selected as the main reason for joining a trial, the free text comments 
shows that it was interwoven with wanting to also help individuals themselves, as these quotes 
illustrate:- 
“I am happy to take part in any trial that may benefit not only me, but others who may need to 
have treatment for cancer”, ID 08 
“ I am very pleased to be asked to take part in these trials as I think they will be beneficial to 
myself e.g. having extra scans, blood tests etc. and to help other people with my illness on the 
outcome of the trials”. ID 66 
Patients’ satisfaction with communication about trial information was very good, irrespective of 
participation decision, or trial type (Table 4).  
Discussion 
The majority of women returning questionnaires had decided to participate in a randomised 
clinical trial as part of their treatment plan. Those who declined trial entry were more likely to be 
worried about randomisation, felt less strongly about helping with the doctor’s research, and did 
not agree as strongly that the benefits of treatment would outweigh the side effects. Importantly 
women who declined were as satisfied with the information received, and the clarity of it, as 
those who agreed to participate.  
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Previously we reported a significantly higher acceptance rate for trials with an active treatment 
arm, compared with trials that had a no treatment or placebo group [9]; however this included 
patients with all solid common tumours. The current analysis focused only on women with 
breast cancer, and although there were no significant differences in acceptance rates between 
trial types, numerically fewer women accepted trials that offered standard therapy plus or minus 
a new treatment as a primary therapy following breast cancer surgery. The trials in question 
were radiotherapy to the chest wall and axilla following mastectomy, and ovarian protection for 
premenopausal women having chemotherapy.  
Irrespective of trial decision, all patients indicated that they trusted the doctor treating them and 
was the main reason given by decliners, suggesting that these doctors had provided a very 
even handed explanation of the trial and stressed the voluntary nature of participation 
convincingly. Women who had accepted trial participation stated that they wanted to help others 
in the future, although believed the trial offered them the best treatment too, which perhaps 
allowed them to feel more altruistic. While it is possible that many patients with cancer are 
genuinely selfless, it must be highlighted that social desirability may influence endorsement of 
altruistic statements if these are provided as options on a questionnaire. The authors of one 
study coined the term ‘conditional altruism’ to describe the situation where people agree to 
randomisation as an opportunity to help others but hopefully themselves or at least not do 
themselves harm from participation (15).Of course patients who participate in questionnaire 
research may be more positively inclined to research in general, including clinical trials, which 
may have given us a bias sample, in that those who did not return questionnaires may also 
have declined trial entry.   
In the UK, many discussions with patients about breast cancer trials take place over time with 
various members of a cancer team; both formal and informal. This is of enormous benefit if 
team members are supportive and knowledgeable about the trial, but detrimental if unclear or 
have an antipathy toward the trial [1816].  Virtually all new trials have sub-studies that may need 
extra tumour samples taken, more histo-pathology and additional imaging or other screening 
tests. This leads to greater patient burden, involving more hospital visits for tests, and involves 
complex information giving for the health care professionals [11]. Often the content and 
readability of trial recruitment resources is at too high a reading level [1917], and health 
professionals overestimate their patients’ health literacy skills [2018]. In addition, the fact that 
poor functional health literacy can imply problems in understanding oral communication is 
overlooked [2119]. There have been various efforts to circumvent these problems such as 
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employing educational interventions to improve health care professionals’ general 
communication skills, and their discussions about trials with patients and members of their own 
cancer team [14, 2220, 2321].  Also required is information in a more accessible format that 
compliments the trial information sheets but enables patients to revisit sections easily. One such 
resource is patient information DVDs, developed for specific cancer trials.  We have produced 
several with input from patients, the lay public, and trial management committees. They are 
particularly useful when a trial is predicted to be one that may, because of the complexity of the 
design heighten communication difficulties with patients. For example, surgical trials have 
struggled or failed to recruit sufficient patients due to the very different treatment arms on offer 
and a perception by patients, in the context of life threatening disease, that ‘doing something’ or 
something more radical, must surely be better than just ‘waiting for something to happen’.  The 
trial information DVDs are patient friendly; include graphics and simple illustrations of 
randomisation, the logic for the trial, the difference between the groups and other trial 
information. Some also include a session with the Chief Investigator of the study answering 
further questions from women contemplating the trial.  
Conclusion 
This small study did demonstrate that if approached most women with breast cancer are 
generally willing to participate in both adjuvant and advanced disease RCTs. Furthermore trial 
design did not appear to have a significant impact. Women with breast cancer in this sample 
were primarily motivated by altruism. As in other research, randomisation seems to be the 
primary deterrent. Good educational aides as well as communication might assist in explaining 
the need, scientific logic for chance allocation and safety of the approach. 
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Table 1: Characteristics of participants 
  Breast 
(n=152) 
Age group 
29-50yrs 
51-69yrs 
70+ yrs 
missing 
 
28 (21) 
84 (65) 
18 (14) 
21  
Treatment aim 
primary 
further for advanced disease 
missing 
 
110 (79) 
  30 (21) 
  12   
Trial type 
placebo controlled  
std vs std given at different duration or different therapy 
std vs std +/ - new agent 
missing 
 
45 (33) 
67 (49) 
25 (18) 
15  
Take part in trial 
yes 
no 
don’t know 
 
113 (74) 
  31 (20) 
    8  (5) 
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Table 2: Example of breast trials, type and overall acceptance rates 
Trial Design Acceptance  Examples of trials within that design 
standard therapy versus 
standard +/- novel drug 
16/25 
(64%) 
OPTION – chemotherapy +/- goserelin  
SUPREMO – mastectomy +/- radiotherapy to the 
chest wall  
standard versus new 
therapy or regimen 
54/67  
(81%) 
AMAROS – axillary radiotherapy v axillary lymph 
node dissection  
PERSEPHONE - 12 versus 6 months 
trastuzumab 
placebo control 33/45 
 (73%) 
REACT - double blind RCT celecoxib versus 
placebo 
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Table 3: Table showing proportion of participants agreeing to each statement divided 
into those who accepted or declined trial entry (don’t knows were excluded) 
(x2, Fisher’s exact) 
Statement Accept 
(n=113) 
Decline 
(n=31) 
P 
value 
1. I thought the trial offered the best 
treatment available 
90/108~ 
(83%) 
10/31 
(32%) 
<.001 
2. I believed the benefits of 
treatment in the trial would 
outweigh the side effects 
98/111** 
(88%) 
12/31 
(39%) 
<.001 
3. I was satisfied that either 
treatment in the trial would be 
suitable 
102/111** 
(92%) 
14/31 
(45%) 
<.001 
4. I was worried that my illness would 
get worse unless I joined the trial 
12/108~ 
(11%) 
2/31 
(7%) 
.735 
5. The idea of randomisation 
worried me 
22/111** 
(20%) 
12/31 
(39%) 
.035 
6. I wanted a dr to choose my treatment 
rather than be randomised by computer 
34/111** 
(31%) 
16/30* 
(53%) 
.031 
7. The dr told me what I 
needed to know about the trial 
107/111** 
(96%) 
30/31 
(97%) 
1.00 
8. I trusted the dr treating me 111/111** 
(100%) 
30/30* 
(100%) 
- 
9. I was given too much 
information to read about the trial 
9/108~ 
(8%) 
1/30* 
(3%) 
.69 
10. I was given enough 
information to read about the trial 
109/112* 
(97%) 
30/31 
(97%) 
1.00 
11. I knew I could leave the trial at any 
time and still be treated 
111/111** 
(100%) 
29/31 
(94%) 
.046^ 
12. I did not feel able to say no 7/110*** 
(6%) 
0/31 
(0%) 
.347 
13. I wanted to help with the dr’s 
research 
112/112* 
(100%) 
17/30* 
(57%) 
<.001 
14. I feel that others with my illness will 
benefit from the results of trial 
111/111** 
(100%) 
29/31 
(94%) 
.046^ 
15. The dr wanted me to join the trial 44/107# 
(41%) 
12/30* 
(40%) 
1.00 
16. Others, for example, family or 
friends, wanted me to join the trial 
60/108~ 
(56%) 
3/30* 
(10%) 
<.001 
* 1 response missing 
** 2 responses missing 
***3 responses missing 
~5 responses missing 
#6 responses missing 
 
^ caution is required interpretation when interpreting significance due to multiple analyses  
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Table 4: Table showing proportion of participants who either accepted or declined trial 
entry, agreeing to each statement about the clarity of trial communication (x2, Fisher’s 
exact) 
 Statement Accept 
(n=113) 
Decline 
(n=31) 
P  
value 
1.The HCP used clear and understandable  language 113* 
(100%) 
31 
(100%) 
 
2.I understood that entry into the trial was voluntary 113 
(100%) 
31 
(100%) 
- 
3. I understood if I agreed to join the trial I could leave at any time 113 
(100%) 
29 
(93%) 
.045 
4. I understood the HCP’s explanation of randomisation 113 
(100%) 
31 
(100%) 
- 
5. I felt the HCP was sensitive to my concerns 113 
(100%) 
31 
(100%) 
= 
6. I was given the opportunity to ask questions 112/113  
(99%) 
31 
(100%) 
1.00 
7. I was left confused 0 0 - 
8. I felt the HCP listened to what I had to say 111/111** 
(100%) 
31 
(100%) 
- 
9. I understood the treatment options available outside the trial 106/110*** 
(96%) 
28 
(90%) 
0.179 
10. I was informed about possible side effects of the different 
treatments 
105/110***  
(95%) 
27 
(87%) 
0.107 
11. The HCP seemed to favour one treatment over another 4/106****  
(4%) 
1 
(3%) 
1.00 
12. I felt that HCP gave me all the information I needed to make 
decision 
111  
(100%) 
31 
(100%) 
- 
13. I felt that the HCP created an atmosphere of trust and support 110/111  
(99%) 
31 
(100%) 
1.00 
14. I felt that the HCP gave me time to consider entry into the trial 111  
(100%) 
31 
(100%) 
- 
15. I still have unanswered questions 2/107****  
(2%) 
2 
(7%) 
.199 
*1 missing response 
**2 missing responses 
     *** 3 missing responses 
**** 4 or more missing responses 
 
 
 
 
 
